Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial

(2021) Corinne Faivre-Finn et al.   Journal of Thoracic Oncology

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates

(2021) Shijie Shang et al.   Cancer Communications

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

(2020) Hailong Sheng et al.   Journal for ImmunoTherapy of Cancer

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

(2020) Gaia Giannone et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies

(2020) Valerio Gelfo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy

(2020) Rebekka Weber et al.   CELLULAR IMMUNOLOGY

TEMPORARY REMOVAL: IFN-γ: A cytokine at the right time, is in the right place

(2019) J. Daniel Burke et al.   SEMINARS IN IMMUNOLOGY

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

(2019) Willemijn S. M. E. Theelen et al.   JAMA Oncology

Immuno-oncology drug development goes global

(2019) Jia Xin Yu et al.   NATURE REVIEWS DRUG DISCOVERY

Cancer immunotherapy: broadening the scope of targetable tumours

(2018) Jitske van den Bulk et al.   Open Biology

Interleukin-1 Beta—A Friend or Foe in Malignancies?

(2018) Rebekka Bent et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

(2018) Arianna Calcinotto et al.   NATURE

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters

(2017) Gabor J. Szebeni et al.   MEDIATORS OF INFLAMMATION

Recent Developments in Radiotherapy

(2017) Deborah E. Citrin   NEW ENGLAND JOURNAL OF MEDICINE

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Cytotoxic T Lymphocytes Block Tumor Growth Both by Lytic Activity and IFN -Dependent Cell-Cycle Arrest

(2014) H. Matsushita et al.   Cancer Immunology Research

Is tumor (R)ejection by the immune system the “5th R” of radiobiology?

(2014) Encouse Golden et al.   OncoImmunology

Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?

(2009) Mitchell Kamrava et al.   Molecular BioSystems